Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The dynactin 4 pseudogene (ENSG00000227722) is a non-functional genomic sequence derived from the dynactin 4 gene (DCTN4), which encodes the p62 subunit of the dynactin complex. As a pseudogene, it has lost protein-coding capacity due to deleterious disruptions such as premature stop codons or frameshift mutations in its open reading frame[1]. Despite being considered "non-functional," this pseudogene may be transcribed to produce non-coding RNAs that could influence gene expression through various mechanisms[1]. Pseudogenes like this one can function as competing endogenous RNAs (ceRNAs), potentially affecting the expression of their parent genes through positive correlations in transcriptional profiles[1]. They may also produce small RNAs that can interfere with gene expression or participate in chromatin modification through recruitment of histone methyltransferases and establishment of repressive chromatin environments[1]. The parent dynactin 4 gene encodes a crucial component of the dynactin complex, which acts as an activator of cytoplasmic dynein and is involved in intracellular transport, mitosis, and nuclear migration[2]. The dynactin 4 subunit contains zinc-binding motifs and is part of the pointed-end complex of the dynactin structure[2]. While the pseudogene itself is not a therapeutic target, understanding its regulatory role may provide insights into cellular processes and potential disease mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dynactin 4 pseudogene (ENSG00000227722).